Durvalumab and Tremelimumab + Doxorubicin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Adult Soft Tissue Sarcoma
Conditions
Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma
Trial Timeline
Dec 15, 2017 → Aug 12, 2022
NCT ID
NCT03317457About Durvalumab and Tremelimumab + Doxorubicin
Durvalumab and Tremelimumab + Doxorubicin is a phase 2 stage product being developed by AstraZeneca for Metastatic Adult Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03317457. Target conditions include Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03317457 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic Adult Soft Tissue Sarcoma